Yi, RenliangChen, BaoxinDuan, PengZheng, ChanjiaoShen, HuanyuLiu, QunYuan, ChenOu, WeilinZhou, Zhiheng2017-02-182016Yi, Renliang, Baoxin Chen, Peng Duan, Chanjiao Zheng, Huanyu Shen, Qun Liu, Chen Yuan, Weilin Ou, and Zhiheng Zhou. 2016. “Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.” Journal of Immunology Research 2016 (1): 4543861. doi:10.1155/2016/4543861. http://dx.doi.org/10.1155/2016/4543861.2314-8861http://nrs.harvard.edu/urn-3:HUL.InstRepos:30370928New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR-directed therapies in patients with CRPC. RevMan 5.1 was used for pooled analysis and analysis of publication bias. Seven studies were included in the meta-analysis, with three studies in sipuleucel-T (totally 737 patients, 488 patients in treatment group, and 249 patients in placebo group) and four in AR-directed therapies (totally 5,199 patients, 3,015 patients in treatment group, and 2,184 patients in placebo group). Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increased risk of adverse event of grade ≥3 (p > 0.05). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level ≥50% was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%. AR-directed therapies did not increase risk of adverse event of grade ≥3 (p > 0.05).en-USJournal Article2017-02-1810.1155/2016/4543861